32.75
-0.98(-2.91%)
Currency In USD
| Previous Close | 33.73 |
| Open | 33.6 |
| Day High | 34.21 |
| Day Low | 31.88 |
| 52-Week High | 38.93 |
| 52-Week Low | 16.54 |
| Volume | 462,638 |
| Average Volume | 274,926 |
| Market Cap | 921.79M |
| PE | 49.62 |
| EPS | 0.66 |
| Moving Average 50 Days | 29.58 |
| Moving Average 200 Days | 27.61 |
| Change | -0.98 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $2,021.6 as of July 16, 2025 at a share price of $32.75. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $1,462.05 as of July 16, 2025 at a share price of $32.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
GlobeNewswire Inc.
Jul 07, 2025 12:00 PM GMT
Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net salesSAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LEN
LENZ Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewswire Inc.
May 09, 2025 1:03 PM GMT
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net salesSAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ)